Aurobindo Pharma Australia Pty Limited, the fully-owned subsidiary of Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), Aurobindo Pharma Limited, has received its first approval from the Therapeutic Goods Administration (TGA), Australia, for the registration of Auro-Lisinopril 5 mg, Auro-Lisinopril 10 mg and Auro-Lisinopril 20 mg tablets.
The approved indications for these therapeutic products are for treatment of hypertension, congestive heart failure and acute myocardial infraction, the company said in a filing to the BSE on Monday.
